It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: Restricted
Think how many people this nurse came in contact with. Use your head.
originally posted by: Staroth
A good friend of mine lives in Dallas and just wrote
"Pretty sure I just found out about a third case. One of my friends was woke up by the cdc because his neighbor tested positive. Not sure if it's the same person or not... ugh. This hospital is about 7 minutes from my driveway.... my son was born there"
You won't see that on the news! At least not yet.
originally posted by: BlueAjah
From the press conference:
There is a pet in the nurse's home
In the press conference they said they would be "taking care" of that later today. When he said it, hesitatingly, he looked sad.
Another innocent victim like the spanish nurse's dog?
originally posted by: CardiffGiant
not contagious if youre not showing symptoms
Two promising candidate vaccines
Given the public health need for safe and effective Ebola interventions, WHO regards the expedited evaluation of all Ebola vaccines with clinical grade material as a high priority.
Two candidate vaccines have clinical-grade vials available for phase 1 pre-licensure clinical trials.
One (cAd3-ZEBOV) has been developed by GlaxoSmithKline in collaboration with the US National Institute of Allergy and Infectious Diseases. It uses a chimpanzee-derived adenovirus vector with an Ebola virus gene inserted.
The second (rVSV-ZEBOV) was developed by the Public Health Agency of Canada in Winnipeg. The license for commercialization of the Canadian vaccine is held by an American company, the NewLink Genetics company, located in Ames, Iowa. The vaccine uses an attenuated or weakened vesicular stomatitis virus, a pathogen found in livestock; one of its genes has been replaced by an Ebola virus gene.
The overarching objective was to take stock of the many efforts currently under way to rapidly evaluate Ebola vaccines for safety and efficacy. The next step is to make these vaccines available as soon as possible – and in sufficient quantities – to protect critical frontline workers and to make a difference in the epidemic’s future evolution.
Source: Moscow (AFP) - Russia expects to produce three Ebola vaccines within the next six months, Health Minister Veronika Skvortsova said on Saturday.
“We have created three vaccines… and we think they will be ready in the next six months,” the minister said on Rossiya 1 television.
“One of them is already ready for a clinical trial,” she said.
One of the vaccines was developed from an inactive strain of the virus, the minister added.
The current outbreak of Ebola, the worst on record, has claimed more than 4,000 lives since the start of the year, mainly in the west African nations of Guinea, Liberia and Sierra Leone.
There is no licensed treatment for the highly contagious disease, but several countries are trying to develop an effective vaccine.
Russia, which has not had any cases of Ebola, sent a team of scientists and a mobile laboratory to help fight the disease in Guinea at the end of August.
Russia has also implemented a protection plan against the virus, which it stepped up in July, according to the minister.
Seventy-one Russian airports were equipped with thermal cameras to detect the first signs of the virus, she said.
More than 450 students from west Africa studying in Russian universities were under constant surveillance, she added.
The first trial of an experimental Ebola vaccine has begun in Africa, as three health care workers from Mali infected with the deadly disease that's spreading through the western part of the continent became the first sufferers to receive it. The vaccine, which was developed in the U.S., is expected to be given to another 34 health care workers in the coming weeks.
The vaccine trial started Wednesday, according to the medical school. It was developed by investigators at the National Institute of Allergy and Infectious Disease’s Vaccine Research Center in Bethesda, Maryland after two months. Before Wednesday, the vaccine was only tested on animals.
The vaccine includes a type of cold virus known as adenovirus that doesn’t cause humans to become ill. The virus is modified so it produces an attachment protein of the Ebola virus.
“Immune responses directed against this single Ebola protein have been shown to be highly protective in animal model challenge studies,” the medical school said.
originally posted by: Restricted
a reply to: CardiffGiant
All you do in these threads is play advocatus diaboli. Your avatar is fitting.
Perhaps we should send a few patients to Wales, or wherever you live. You'd probably feel differently.